NCT05362916View on ClinicalTrials.gov

Letermovir in ART-treated HIV-infected Persons

NACompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

September 26, 2022

Primary Completion Date

January 27, 2025

Study Completion Date

January 27, 2025

Conditions
People Living With HIV
Interventions
DRUG

Letermovir

Participants in the treatment arm will take either 1 tablet of 480mg PO once daily or 2 tablets of 240mg PO once daily.

Trial Locations (1)

H4A 3J1

Mcgill University Health Center, Montreal

All Listed Sponsors
lead

Jean-Pierre Routy

OTHER